Medical Licensing (MD/DO) · Independent exam preparation
ABA Initial Pain Medicine Examination: Clinical Decisions Guide Study Guide
Practise pain-mechanism diagnosis, medication selection, procedural safety, and rehabilitation decisions for the ABA initial Pain Medicine subspecialty examination.
By CertMedbry · Updated 15 October 2026
Distinguish pain mechanisms, recognize urgent neurologic findings, choose safer analgesic strategies, and connect procedures with measurable functional goals. This selective guide develops 60 clinical concepts across every blueprint domain for the ABA initial Pain Medicine subspecialty examination. The official November 2024 content outline defines the full examination scope, including topics beyond this guide.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification examination does this guide cover?
The ABA initial Pain Medicine Examination assesses physician subspecialty practice. It is not a general medical licensure examination. ABA BASIC, ADVANCED, subspecialty in-training examinations, ASPEX recertification, and the separate American Board of Pain Medicine credential are outside this guide's scope. Requirements of another certifying board or pathway should not be inferred from this ABA listing.
How many questions are there, and how long is the examination?
The blueprint specifies 200 questions and up to four hours. It does not identify a scored-versus-pretest question split or specify a passing score, fee, or additional timing allowance.
How is the examination delivered?
The blueprint describes an annual, single-day, computer-based examination administered at Pearson VUE centers nationwide in the United States. It does not describe an adaptive algorithm; adaptivity should therefore not be assumed.
What question styles should candidates expect?
The blueprint describes A-type single-best-answer questions emphasizing clinical application, often using a clinical vignette and three response options. Some questions reference static images. This guide provides four-option, text-only independent MCQ drills, so its option count and media presentation differ from the issuer's stated format.
Which outline version and blueprint dates apply?
The outline is dated November 2024. The accompanying issuer-linked blueprint states no effective or implementation date; its URL upload directory does not establish one. The outline references the IASP 2005 curriculum while explaining that examination items are revised as science and practice change. Its acute-pain section says Postoperative Pain, whereas the blueprint domain says Procedural Pain; this guide uses the blueprint label.
Pain Medicine Examination Content Outline — November 2024 · ABA Pain Medicine Exam Blueprint
How is content weighted?
General and Clinical States each contribute 50%. General comprises Background Concepts 5%, Assessment of Pain 5%, Pharmacotherapy 15%, Procedural Treatment 15%, and Psychological, Physical, and Integrative Therapies 10%. Clinical States comprises Taxonomy 1%, Chronic Widespread Pain 1%, Acute/Trauma/Procedural Pain 6.5%, Musculoskeletal Pain 12.5%, Cancer Pain 6%, Visceral Pain 4%, Headache/Orofacial Pain 3%, Neuropathic Pain 8%, and Special Cases 8%. Within pharmacotherapy, the blueprint assigns comparable ranges of 7–9 questions each to opioids, antipyretic analgesics, antidepressants/anticonvulsants, and other analgesic pharmacotherapy.
How closely do these learning materials follow those weights?
The 60 concepts divide into 30 General entries and 30 Clinical States entries. General domain counts are 3 Background, 3 Assessment, 9 Pharmacotherapy, 9 Procedural, and 6 Psychological/Physical/Integrative. Clinical States counts are 1 Taxonomy, 1 Widespread Pain, 4 Acute Pain, 7 Musculoskeletal, 3 Cancer, 2 Visceral, 2 Headache, 5 Neuropathic, and 5 Special Cases. The 20 questions divide equally between General and Clinical States: General has 2 Assessment, 3 Pharmacotherapy, 3 Procedural, and 2 Psychological/Physical/Integrative questions; Clinical States has 1 Acute, 3 Musculoskeletal, 1 Cancer, 1 Visceral, 1 Headache, 2 Neuropathic, and 1 Special Cases question. Flashcards represent every domain. Small sets require rounding and do not reproduce an examination form or exhaust the official outline.
Pain Medicine Examination Content Outline — November 2024 · ABA Pain Medicine Exam Blueprint
This is independent educational material for the ABA physician subspecialty certification pathway. The questions and flashcards are original learning exercises, without ABA endorsement or pass prediction.
Outline used: November 2024 Content Outline and currently issuer-linked Pain Medicine Exam Blueprint, which states no effective or implementation date. Live checked on 2026-10-09 in Asia/Hong_Kong. The workbook label maps to the ABA initial Pain Medicine subspecialty certification examination; the assigned canonical slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Background Concepts5%
1.How does pain differ from nociception?
Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Nociception is neural encoding of noxious stimuli. The processes are related but not interchangeable: neural activity alone does not establish a person's experience, and pain can persist without continuing tissue injury. Assessment therefore integrates the person's account, clinical context, function, and communication abilities rather than demanding a visible lesion before acknowledging pain.
Apply it
A patient reports persistent pain after a healed incision. Explain that tissue healing and pain resolution can follow different courses, then assess sensory findings, function, sleep, and alternative causes rather than dismissing the complaint.
Common pitfall: A normal scan does not demonstrate absence of pain. Conversely, observing a nociceptive reflex does not directly measure the intensity or meaning of experienced pain.
2.What distinguishes peripheral from central sensitization?
Peripheral sensitization increases the responsiveness and lowers the threshold of peripheral nociceptive neurons. Central sensitization increases responsiveness of nociceptive neurons within the central nervous system to normal or subthreshold afferent input. Both can amplify pain, but their locations and implications differ. Tenderness near inflamed tissue can reflect peripheral changes, whereas amplified responses extending beyond the original region may suggest central processing changes. Clinical findings suggest mechanisms without directly measuring neuronal sensitization.
Apply it
After an ankle injury, a patient develops marked tenderness locally and sensitivity extending beyond the injured tissues. Separate the evidence for ongoing peripheral pathology from possible amplified central processing when explaining the examination and planning rehabilitation.
Common pitfall: Allodynia is a clinical observation, not a direct assay of central sensitization. Do not use one sensory finding to exclude continuing peripheral disease.
3.How does absolute benefit change interpretation of a pain trial?
Relative effects need an absolute baseline to show practical benefit. If meaningful improvement occurs in 50% of treated participants and 30% of controls, the absolute benefit increase is 20 percentage points and the number needed to treat is five. Interpret that result alongside the response definition, confidence interval, follow-up duration, harms, and study population. Statistical significance alone does not establish a clinically important improvement or applicability to a patient excluded from the trial.
Apply it
A treatment advertisement emphasizes a large relative improvement. Recalculate benefit from the actual responder proportions, then check whether response meant worthwhile functional improvement and whether participants resembled the patient considering treatment in your clinic.
Common pitfall: A small probability value does not quantify treatment magnitude. Number needed to treat also changes with baseline risk, follow-up time, and the chosen outcome.
Pain Medicine Examination Content Outline — November 2024 · Chapter 15: Interpreting results and drawing conclusions | Cochrane
Assessment of Pain5%
4.Which examination findings distinguish allodynia from hyperalgesia?
Allodynia is pain caused by a stimulus that normally does not provoke pain, such as light brushing. Hyperalgesia is increased pain from a stimulus that normally provokes pain, such as pinprick. The distinction depends on the stimulus and response, not simply the reported severity. Document stimulus type, distribution, and comparison with an unaffected region. These observations characterize sensory processing but do not independently identify the underlying lesion or establish a specific pain syndrome.
Apply it
A patient finds cotton brushing painful and reports exaggerated pain with pinprick around a scar. Record dynamic mechanical allodynia and pinprick hyperalgesia separately, then determine whether the distribution fits an injured cutaneous nerve.
Common pitfall: Calling every exaggerated response hyperalgesia loses information. A normally innocuous stimulus producing pain meets allodynia terminology even when its perceived intensity is relatively mild.
5.Why should pain intensity and function be measured separately?
Pain intensity measures one dimension of the experience, whereas function concerns activities and participation. A treatment can improve walking, sleep, or work tolerance without eliminating pain, and sedation can lower reported intensity while worsening participation. Establish meaningful baseline activities and reassess them alongside pain, adverse effects, and mood. The decision to continue treatment should reflect the whole benefit-burden balance rather than a numerical pain score considered in isolation from daily life.
Apply it
After a medication change, a patient's pain falls slightly but daytime somnolence prevents driving and working. Compare these outcomes with the agreed goals before interpreting the lower score as evidence that treatment should continue.
Common pitfall: Unchanged pain intensity does not automatically mean treatment failed. Equally, a lower score cannot justify continuing therapy that substantially worsens safety or daily functioning.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · Pain Medicine Examination Content Outline — November 2024
6.Why does improvement after treatment not establish a specific effect?
Symptoms fluctuate, and people often seek care during an unusually severe period. Subsequent improvement can therefore reflect regression to the mean, natural history, expectations, contextual effects, or a specific treatment action. A before-and-after observation cannot separate these contributors. Compare outcomes against an appropriate control when judging efficacy, and use repeated functional measurements when following an individual. A contextual response is compatible with real pain and does not demonstrate deception or an exclusively psychological origin.
Apply it
A patient's back pain improves after an intervention performed during a major flare. Acknowledge the improvement while tracking function over time and avoiding the conclusion that this single response proves the procedure's specific mechanism.
Common pitfall: A placebo response does not show that pain was imaginary. Absence of a control group also prevents attributing every improvement to the active treatment.
Pain Medicine Examination Content Outline — November 2024 · IASP Announces Revised Definition of Pain
Treatment of Pain: Pharmacotherapy15%
7.How should opioid benefit, dependence, and treatment transitions be assessed?
For outpatient pain within the CDC guideline's scope, continuation requires individualized reassessment of pain, function, sedation, interactions, and patient priorities. Offer naloxone particularly with previous overdose, substance use disorder, sleep-disordered breathing, higher exposure, concurrent benzodiazepines, or reduced tolerance after interruption. Physical dependence causes withdrawal after reduction; tolerance is diminished effect with repeated exposure. Neither alone establishes opioid use disorder, and tolerance and withdrawal are not counted toward that diagnosis during appropriate medical supervision. If tapering is indicated, collaborate on a gradual individualized plan with continued care, monitoring, and adjustment. Avoid abrupt discontinuation or rapid reduction unless a life-threatening concern requires urgent action. The CDC guideline excludes sickle cell disease, cancer-related pain treatment, palliative care, and end-of-life care.
Apply it
A patient with chronic back pain has unchanged walking tolerance and increasing drowsiness on long-term opioids. Review interactions and overdose risk, offer naloxone with household education, and discuss a monitored taper if burdens outweigh benefits. Withdrawal during a previous interruption warrants planning for dependence, not an automatic addiction diagnosis.
Common pitfall: A high pain score alone does not justify escalation. Naloxone does not make hazardous combinations safe, and a taper must not become abandonment or a mandatory administrative deadline.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
8.How do ketamine and corticosteroids differ as adjuvant analgesics?
Ketamine antagonizes NMDA receptors and can modify excitatory pain transmission and sensitization. Its use for refractory cancer pain is limited by uncertain net benefit, psychotomimetic effects, delirium, hypertension, tachycardia, sedation, and CYP3A4-related interactions. A plausible mechanism does not establish efficacy for every chronic pain condition. Corticosteroids such as dexamethasone act through anti-inflammatory and edema-reducing effects and may be selected for particular cancer pain contributors, including peritumoral edema. Evidence for general cancer analgesia is limited. Hyperglycemia, insomnia, immunosuppression, and psychiatric effects matter early; prolonged exposure adds myopathy and osteoporosis. Dexamethasone has relatively little mineralocorticoid activity but still has cytochrome P450 interactions.
Apply it
For cancer pain with an edema-related component, weigh a targeted corticosteroid trial against diabetes, infection risk, and weakness. For refractory pain being considered for ketamine, establish the intended outcome and review blood pressure, mental status, interacting medicines, and the limited evidence for that indication.
Common pitfall: These drugs address different mechanisms and carry different risks. Neither should be added indefinitely merely because standard analgesia has been insufficient; reassess benefit and toxicity against the specific indication.
9.How do opioid mechanisms and renal function change drug choice?
Methadone combines mu-opioid receptor agonism with NMDA receptor antagonism. Its long, variable elimination half-life permits delayed accumulation, so an initially tolerated regimen can still produce later toxicity. Renal impairment can allow morphine and hydromorphone metabolites to accumulate, contributing to neurotoxicity. Methadone has less dependence on renal elimination, but interactions, QT prolongation, and variable opioid conversion ratios complicate selection. Analgesic mechanism, metabolite clearance, and the time course of accumulation must therefore be considered together.
Apply it
New myoclonus or confusion during morphine treatment, particularly with declining renal function, warrants assessment for opioid toxicity and other causes. Review the medication history, organ function, and interacting drugs before revising the regimen or selecting an alternative.
Common pitfall: Hydromorphone is not metabolite-free. A comparatively favorable renal profile does not establish a safe methadone conversion, and simple equianalgesic arithmetic does not account for its variable conversion ratios or delayed accumulation.
10.How do gabapentinoids differ from sodium-channel-blocking anticonvulsants?
Gabapentin and pregabalin bind the alpha-2-delta subunit of voltage-gated calcium channels; they do not bind GABA receptors. Both require renal dose adjustment and can cause sedation, dizziness, and peripheral edema. Opioids and other central nervous system depressants increase their respiratory risk, especially with respiratory impairment or older age. Sodium-channel blockers such as oxcarbazepine, lamotrigine, and lacosamide instead limit neuronal excitation through sodium-channel effects. The AAN recognizes this as another effective class for painful diabetic polyneuropathy; nausea, fatigue, and dizziness may limit selection. Class evidence does not make every member equally suitable: valproate's teratogenic and other serious toxicities substantially restrict its use for this indication.
Apply it
An older adult with lung disease, renal decline, and an opioid prescription becomes difficult to awaken after pregabalin is added. Urgently assess breathing and sedating medicines. If later selecting another neuropathic treatment, compare a different effective class rather than assuming all anticonvulsants share pregabalin's mechanism or renal handling.
Common pitfall: An opioid-sparing drug can still increase respiratory risk. Sodium-channel blockers and gabapentinoids are distinct classes, and evidence of class efficacy does not remove drug-specific contraindications.
FDA Gabapentinoid Drug Safety Communication — Serious Breathing Problems · AAN Oral and Topical Treatment of Painful Diabetic Polyneuropathy — Practice Guideline Update · NCI Cancer Pain — Health Professional PDQ
11.Why are NSAIDs hazardous during dehydration?
NSAIDs reduce prostaglandin synthesis through cyclooxygenase inhibition. Ibuprofen and naproxen are common nonselective examples; celecoxib is COX-2 selective. Renal prostaglandins help maintain blood flow when circulating volume or renal perfusion is reduced. Inhibiting this compensation increases acute kidney injury risk during dehydration or hypovolemia. COX-2 selectivity does not remove renal vulnerability. Chronic kidney disease and interacting medications can further increase risk. Medication review must include over-the-counter products because patients may not recognize them as NSAIDs.
Apply it
A patient with chronic kidney disease takes ibuprofen for back pain during several days of vomiting and poor intake. Identify the combination of reduced volume and NSAID exposure as a renal safety concern requiring prompt assessment.
Common pitfall: Previous tolerance of an NSAID does not establish safety during a dehydrating illness. The relevant risk can change rapidly with circulating volume and kidney function.
NIDDK Keeping Kidneys Safe: Smart Choices about Medicines · FDA Caldolor (Ibuprofen) Prescribing Information — 2026 · NCI Cancer Pain — Health Professional PDQ
12.How do acetaminophen and NSAID risk profiles guide selection?
Acetaminophen provides analgesic and antipyretic effects; its precise analgesic mechanism is not fully established. It is not selected for the peripheral anti-inflammatory effect supplied by NSAIDs. Its hepatic risk and the total exposure from combination products require review. Systemic NSAIDs can cause gastrointestinal ulceration or bleeding, hypertension, fluid retention, and renal injury. Celecoxib has less antiplatelet activity and may have a more favorable gastrointestinal profile than nonselective NSAIDs, but this does not eliminate renal or cardiovascular concerns. Review ulcer history, bleeding risk, cardiovascular status, kidney and liver function, volume status, and concurrent medicines. Route and exposure also matter: a topical knee OA recommendation cannot be generalized to every painful anatomical site.
Apply it
A patient with knee osteoarthritis, previous ulcer bleeding, and hypertension asks for an oral NSAID. Compare a supported topical option and other analgesic choices with systemic risks. If considering acetaminophen, review liver disease and all products contributing to total exposure.
Common pitfall: Absence of dyspepsia does not establish protection against gastrointestinal bleeding. Switching drug class changes the principal risks rather than removing the need for medication reconciliation and organ-function review.
NCI Cancer Pain — Health Professional PDQ · FDA Caldolor (Ibuprofen) Prescribing Information — 2026 · NIDDK Definition and Facts for Peptic Ulcers · 2026 ACR Osteoarthritis Guideline Summary
13.How do TCA and SNRI mechanisms, adverse effects, and trial outcomes guide neuropathic treatment?
TCAs such as amitriptyline and nortriptyline inhibit serotonin and norepinephrine reuptake, enhancing pain-inhibitory pathways. Their anticholinergic, antihistaminic, and antiadrenergic effects contribute to urinary retention, constipation, sedation, and orthostatic hypotension; cardiac disease and interacting anticholinergic or psychoactive medicines add concerns. SNRIs such as duloxetine and venlafaxine also inhibit serotonin and norepinephrine reuptake. Duloxetine is avoided with hepatic impairment or severe renal impairment; venlafaxine can raise blood pressure. Tramadol's monoamine effects warrant particular caution when combined with antidepressants. For painful diabetic polyneuropathy, the AAN supports TCAs, SNRIs, gabapentinoids, and sodium-channel blockers. Failure means an efficacious dose for approximately 12 weeks without clinically significant pain reduction, or adverse effects outweighing benefit. Offer another effective class after failure; useful partial benefit may justify adding a different class after safety review.
Apply it
A patient with urinary retention and orthostatic symptoms has no meaningful benefit from an adequate gabapentinoid trial. A TCA is less attractive because it can worsen these vulnerabilities. Compare an SNRI or another effective class using liver and kidney function, blood pressure, and interacting medicines. If the first drug instead gives useful partial relief, assess whether combination treatment offers net benefit.
Common pitfall: Analgesic use of an antidepressant does not require depression. Do not call a brief low-dose exposure an efficacy failure, continue intolerable treatment for 12 weeks, or overlook cumulative adverse effects when combining classes.
AAN Oral and Topical Treatment of Painful Diabetic Polyneuropathy — Practice Guideline Update · NCI Cancer Pain — Health Professional PDQ
14.How should topical and membrane-stabilizing approaches be distinguished?
Sodium-channel blockade reduces the membrane excitability needed for impulse propagation; local anesthetics and systemic sodium-channel-blocking medicines differ substantially in route, exposure, and safety requirements. A topical local anesthetic strategy addresses a defined painful surface region rather than providing the same exposure as an injection or systemic treatment. Capsaicin is a TRPV1 agonist, a different mechanism from sodium-channel blockade. The AAN includes selected topical approaches, including capsaicin, for patients with painful diabetic polyneuropathy who prefer them; application-site reactions affect tolerability. Match treatment to the condition, painful area, formulation, and supporting evidence. These approaches do not replace assessment of neuropathy, protective sensation, or foot health.
Apply it
A patient with painful feet from diabetic polyneuropathy wishes to avoid another sedating oral medicine. Discuss supported topical options and local tolerability while continuing sensory and foot assessment. Explain that capsaicin and a local anesthetic are different pharmacological approaches.
Common pitfall: Topical does not mean universally harmless. Evidence for one formulation or condition does not validate every compounded cream, and safety expectations for a skin preparation cannot be transferred to systemic local anesthetic administration.
AAN Oral and Topical Treatment of Painful Diabetic Polyneuropathy — Practice Guideline Update · Pain Medicine Examination Content Outline — November 2024 · NCI Cancer Pain — Health Professional PDQ · ASRA Local Anesthetic Systemic Toxicity Checklist — 2020, version 1.1
15.How do bisphosphonates and denosumab differ as bone-targeted adjuncts?
Bisphosphonates such as pamidronate and zoledronic acid inhibit osteoclastic bone resorption and can reduce pain and skeletal-related events in patients with bone metastases. Renal toxicity, electrolyte disturbances, acute-phase symptoms, and osteonecrosis of the jaw affect selection and monitoring. Denosumab inhibits RANKL, reducing osteoclast precursor activation. It is less nephrotoxic and does not require renal dose adjustment, but severe renal dysfunction increases its hypocalcemia risk. Both belong within a broader oncology and analgesic plan rather than serving as sole treatment for uncontrolled focal metastatic pain. Their different targets and organ-related risks provide a useful comparison within other analgesic pharmacotherapy.
Apply it
A patient with painful bone metastases and declining renal function needs a bone-modifying treatment review. Compare bisphosphonate renal toxicity with denosumab-associated hypocalcemia risk, assess calcium and dental concerns, and separately consider radiation or stabilization for a dominant painful lesion.
Common pitfall: Lack of renal dose adjustment does not make denosumab risk-free in kidney disease. A bone-modifying drug does not replace assessment of fracture, instability, or spinal compression.
Treatment of Pain: Procedural15%
16.When should local anesthetic systemic toxicity be suspected?
Local anesthetic systemic toxicity is a potentially life-threatening neurologic and cardiovascular emergency associated with systemic local anesthetic exposure. A seizure, abrupt cardiovascular instability, or arrhythmia during or after local anesthetic administration should prompt recognition and immediate use of a dedicated response protocol. Presentations can vary, so waiting for a complete stereotyped sequence is unsafe. Stop local anesthetic administration, summon help, and prioritize oxygenation, ventilation, seizure control, and lipid rescue according to the ASRA checklist.
Apply it
During a regional injection, a patient develops a generalized seizure followed by an unstable rhythm. Stop injecting, call for emergency assistance, support ventilation, and activate the local anesthetic systemic toxicity response with immediate access to the checklist.
Common pitfall: Do not wait for simultaneous neurologic and cardiovascular findings before acting. Atypical or incomplete presentations still warrant urgent consideration when local anesthetic exposure is temporally related.
ASRA Local Anesthetic Systemic Toxicity Checklist — 2020, version 1.1
17.Why does LAST require a dedicated resuscitation checklist?
ASRA's LAST checklist calls for airway and ventilation support, early consideration of 20% lipid emulsion, and benzodiazepines as the preferred seizure treatment. If epinephrine is needed, smaller doses are preferred, initially below 1 microgram/kg. Avoid additional local anesthetics, beta blockers, calcium channel blockers, and vasopressin. These modifications distinguish LAST management from routine cardiac arrest drug choices. Propofol is not a substitute for lipid rescue. Use the complete checklist for lipid administration, escalation, and observation rather than treating these selected distinctions as a complete resuscitation protocol.
Apply it
During a LAST simulation, the checklist reader identifies the smaller initial epinephrine dose and stops a proposed local-anesthetic antiarrhythmic. Other team members continue airway support, seizure management, circulation support, and lipid rescue.
Common pitfall: A familiar arrest drug can be inappropriate in LAST. Propofol's lipid-containing formulation does not provide the recommended lipid rescue treatment.
ASRA Local Anesthetic Systemic Toxicity Checklist — 2020, version 1.1 · ASRA Checklist for Treatment of Local Anesthetic Systemic Toxicity
18.Why must epidural corticosteroid counseling address neurologic injury?
FDA corticosteroid labeling warns that serious neurologic events have occurred with epidural injection, including spinal cord infarction, paralysis, stroke, and death. Safety and effectiveness for epidural administration have not been established, and corticosteroids are not approved for that use. This does not describe an absolute prohibition of every clinical procedure; it requires accurate discussion of use, alternatives, uncertainty, and potentially catastrophic harms. A procedure's familiarity does not remove the need for specific informed consent.
Apply it
A patient considering an epidural steroid injection believes it is an FDA-approved route because the drug is commercially available. Explain the route-specific status and neurologic risks, then revisit expected benefit, alternatives, and the patient's preferences.
Common pitfall: Approval of a drug product does not establish approval of every route. Do not imply that imaging guidance eliminates the serious neurologic events described in labeling.
19.When should an infected injection site change the plan?
A suspected active infection at the intended corticosteroid injection site changes the procedural risk-benefit assessment. The Kenalog-10 label warns against injection into infected sites. Evaluate local erythema, warmth, drainage, systemic symptoms, and alternative explanations before proceeding with an elective injection. Sterile technique prevents introduction of organisms but does not neutralize an infection that is already present. The appropriate decision is to assess and address the infection rather than treating preparation of the skin as sufficient protection.
Apply it
A patient arrives for an elective joint injection with new warmth, redness, and drainage over the entry area. Pause the injection and arrange assessment of the possible infection rather than attempting to compensate with additional skin antisepsis.
Common pitfall: Routine antiseptic preparation cannot make injection through an infected site appropriate. A pain flare should not automatically be attributed to the established musculoskeletal diagnosis.
20.How should psychosocial screening and a trial inform spinal cord stimulation selection?
The consensus guideline recommends validated psychosocial screening that includes depression, followed by clinical interpretation and treatment of identified needs. Establish realistic expectations and measurable trial goals beforehand. Trial efficacy ordinarily requires at least 50% pain relief measured with a validated instrument. Assess function, tolerability, analgesic use, and satisfaction alongside pain relief. When pain improvement is below 50%, substantial functional improvement of at least 50% or opioid reduction exceeding 50% may support success case by case. These are consensus recommendations, not universal legal or payer requirements. A successful trial supports consideration of implantation but does not guarantee durable benefit.
Apply it
Before a trial, document pain intensity, standing tolerance, and opioid use. A patient whose pain improves by 40% but whose predefined functional measure improves by 60% may qualify for an individualized success determination after considering tolerability and satisfaction. Document why the functional change is substantial and attributable to treatment rather than automatically accepting or rejecting the trial.
Common pitfall: Stimulation sensation alone does not establish efficacy. Depression warrants contextual assessment rather than automatic permanent exclusion, and an exceptional functional or opioid response should not be presented as an automatic substitute for the usual pain-relief threshold.
ASRA Consensus Guidelines on SCS Patient Selection and Trial Stimulation
21.How does procedural bleeding-risk classification change antithrombotic management?
ASRA classifies thoracolumbar facet procedures as low risk, whereas spinal cord stimulation requires higher-risk planning because bleeding near neural structures can cause severe injury. For SCS procedures, ASRA recommends stopping clopidogrel seven days beforehand; a five-day interruption is a rare alternative requiring platelet-function testing to confirm recovery. These intervals concern clopidogrel and cannot be transferred to other antithrombotics. Assess the indication for treatment, thrombotic risk, concurrent medications, and patient bleeding factors. An SCS trial involves lead placement, a period with temporary epidural leads present, and lead removal; planning must address all three stages.
Apply it
For a patient taking clopidogrel, obtain an agreed interruption plan before trial lead placement and explicitly address medication management while the leads remain and at removal. The resumption plan must identify lead removal and satisfactory hemostasis as relevant endpoints. A generic instruction to restart after placement is insufficient for a trial with indwelling leads. If the required interruption cannot safely accommodate the trial and removal, reconsider the elective trial with the prescribing team.
Common pitfall: A prior low-risk facet procedure does not establish safety for SCS. Do not apply a general postprocedure restart interval to lead placement without resolving the remaining trial and removal stages, or independently interrupt essential antiplatelet treatment.
Updates to the ASRA Guidelines for Interventional Pain Procedures
22.How does the diagnostic question determine a spinal block's target?
A block intended to assess a suspected spinal joint source asks a different question from a selective spinal nerve block for radicular pain. Define whether the clinical problem is local spinal pain, somatic referred pain, or ectopic neural pain before selecting an anatomical target. IASP distinguishes identifying an affected nerve from identifying its causative lesion: relief after a selective spinal nerve block may support nerve localization without proving the underlying pathology. Temporary diagnostic relief also differs from evidence that a subsequent lesioning procedure will provide durable benefit.
Apply it
A patient has axial back pain and separate narrow-band shooting leg pain. Describe and assess both components before choosing a block. A response in the leg should not automatically be interpreted as confirmation of the source of the axial pain.
Common pitfall: A joint level, spinal nerve level, and imaging abnormality are not interchangeable diagnostic targets. Record exactly which pain changed, under what conditions, and for how long rather than calling any temporary improvement diagnostic proof.
Pain Medicine Examination Content Outline — November 2024 · PART_I-C.pdf
23.How does visceral pain location guide neurolytic target selection?
Celiac plexus neurolysis is an interventional option for selected patients with upper abdominal pancreatic cancer pain. Selection requires matching the likely visceral pain source and its neural pathways to the proposed target, while considering disease status, procedural risks, treatment goals, and alternative analgesic approaches. A generic nerve block or an intervention for spinal joint pain addresses a different anatomical problem. Cancer pain can also have mixed visceral, somatic, and neuropathic contributors, so one target may not account for the entire presentation.
Apply it
For refractory upper abdominal pancreatic cancer pain, assess whether a celiac plexus intervention fits the pain distribution and goals. Separately evaluate focal bony pain, new neurological findings, or symptoms suggesting obstruction before attributing all pain to the same visceral source.
Common pitfall: Neurolysis does not treat obstruction, fracture, or another cancer emergency. Anatomical plausibility alone does not establish procedural suitability or guarantee comprehensive pain relief.
NCI Cancer Pain — Health Professional PDQ · Pain Medicine Examination Content Outline — November 2024
24.What clinical and regulatory distinctions matter for regenerative injections?
The 2026 ACR summary strongly recommends against PRP and stem-cell injections for knee and hip osteoarthritis. That indication-specific recommendation supports choosing established OA treatments instead of offering those injections as routine care. Separately, FDA warns that the unapproved cellular and related products addressed in its consumer information have not been approved for orthopedic conditions or chronic pain and can cause infection, unwanted immune responses, tumor formation, and other serious harm. FDA registration or a ClinicalTrials.gov listing does not establish product approval. Do not generalize that cellular-product warning into an identical regulatory classification for every injection marketed as regenerative.
Apply it
A patient with knee OA requests PRP or a marketed umbilical-cord cellular injection. Recommend against PRP and stem-cell injections for this indication, discuss established alternatives, and explain that claims of FDA registration do not establish approval of the cellular product for knee OA.
Common pitfall: Clinical efficacy recommendations and regulatory approval answer different questions. Biological plausibility, clinic registration, and a broad marketing label establish neither clinical benefit nor lawful product approval.
2026 ACR Osteoarthritis Guideline Summary · Important Patient and Consumer Information About Regenerative Medicine Therapies | FDA · Pain Medicine Examination Content Outline — November 2024
Treatment of Pain: Psychological, Physical, and Integrative Therapies10%
25.How does cognitive behavioral therapy address pain interference?
Cognitive behavioral approaches examine interactions among interpretations, emotions, behavior, and pain-related disability. Treatment can help a person test catastrophic predictions, build coping skills, and resume valued activities despite symptoms. WHO includes psychological therapies within an individualized package for chronic primary low back pain. Offering this approach acknowledges that pain is influenced by multiple processes; it does not require judging pain to be imaginary or assuming that psychological treatment replaces evaluation of new neurological or systemic findings.
Apply it
A patient with chronic primary low back pain avoids all bending because it is believed to cause inevitable damage. Combine clear education with a psychological approach that tests this prediction and supports gradual return to meaningful movement.
Common pitfall: Presenting psychological treatment as evidence that pain is unreal undermines engagement. The target is often interference, coping, and activity rather than proving a psychological cause.
WHO Releases Guidelines on Chronic Low Back Pain · IASP Announces Revised Definition of Pain
26.How should rehabilitation address CRPS-related sensitivity and movement limitation?
CRPS rehabilitation addresses sensory intolerance, restricted movement, motor difficulties, and loss of daily participation. The outline includes desensitization, paced exercise, occupational therapy, graded motor imagery, and mirror therapy. Select components around the patient's impairments and functional goals, and coordinate analgesic and psychological care so participation is feasible. Progress manageable movement and task practice rather than waiting for complete pain elimination. Reassess unexpected deterioration for another cause instead of assuming every new problem belongs to CRPS.
Apply it
A patient with an assessed CRPS presentation avoids using the affected hand because of touch pain and stiffness. Build tolerable sensory exposure and paced hand use with occupational therapy, consider motor imagery or mirror-based work, and track dressing or meal preparation alongside pain.
Common pitfall: A procedure should not become the entire rehabilitation plan. Neither forced painful activity nor indefinite disuse provides an individualized progression toward useful function.
27.How can pacing support sustained rehabilitation?
Pacing organizes activity into manageable amounts so that participation can become more consistent. It differs from stopping all activity whenever pain is noticed and from doing excessive activity on a good day followed by prolonged inactivity. The outline places pacing alongside graded activity and exercise prescription within rehabilitation. Establish a repeatable baseline, connect progression to meaningful function, and reassess new symptoms that suggest a different clinical problem rather than treating every fluctuation as either harmless or dangerous.
Apply it
A patient alternates between completing all household tasks on one day and resting for the next two. Divide tasks into manageable periods and track consistent participation, then increase capacity gradually as the rehabilitation plan becomes sustainable.
Common pitfall: Pacing should support participation rather than formalize permanent avoidance. A rigid activity schedule also needs reassessment when new neurological findings or another medical problem appears.
28.Why does chronic primary low back pain need a coordinated package?
WHO recommends a holistic, person-centered approach to chronic primary low back pain, using a coordinated package selected for the person's circumstances. Education, exercise, psychological therapies, and other supported interventions can address different contributors to disability. Combining approaches is purposeful when each serves an agreed goal, rather than simply accumulating treatments. The guidance concerns nonsurgical care in primary and community settings; it does not remove the need to investigate red flags or establish whether pain is secondary to a specific disease.
Apply it
A patient has persistent primary low back pain, fear of movement, poor sleep, and difficulty returning to activity. Build a coordinated plan around education, feasible exercise, and psychological support with shared outcomes and clear responsibility for follow-up.
Common pitfall: Multimodal care is not an indiscriminate list of interventions. WHO's primary-pain scope should not be used to bypass assessment of a newly emerging secondary cause.
WHO Releases Guidelines on Chronic Low Back Pain · WHO Guideline for Non-surgical Management of Chronic Primary Low Back Pain
29.How should return-to-work planning address persistent pain?
Work participation depends on task demands, physical capacity, expectations, mood, workplace flexibility, and perceived safety. The outline emphasizes early intervention, identification of obstacles, active rehabilitation, and vocational elements when absence persists. A plan should translate functional assessment into feasible duties and progression rather than requiring complete pain elimination as the only readiness criterion. Communication among the patient, rehabilitation team, and relevant workplace participants can identify practical barriers, while respecting confidentiality and the person's role in decisions.
Apply it
A worker with persistent back pain can perform light tasks but fears returning because the usual job involves heavy lifting. Identify temporary task modifications and graded participation while addressing beliefs about reinjury and tracking actual functional capacity.
Common pitfall: A pain score alone cannot determine work capacity. Equally, a generic instruction to return ignores task demands, available modifications, and barriers that sustain absence.
30.How should complementary therapies enter shared decisions?
Evaluate complementary treatments for a specific indication rather than treating them as one evidence category. The 2026 ACR osteoarthritis summary conditionally recommends acupuncture for knee, hip, and hand osteoarthritis, while conditionally recommending against transcutaneous electrical nerve stimulation for knee and hip osteoarthritis. A conditional recommendation requires discussion of benefits, burdens, uncertainty, and patient preferences; it does not establish guaranteed benefit or a universal prohibition. Neither recommendation establishes the efficacy or safety of an unspecified herbal product, which has different constituents, exposures, and potential adverse effects.
Apply it
A patient with knee osteoarthritis asks about acupuncture, a TENS device, and an herbal mixture. Explain the conditional recommendation favoring acupuncture and the conditional recommendation against TENS for this indication. Continue active rehabilitation. For the mixture, identify the ingredients and doses and assess product-specific evidence and medication interactions before making a recommendation; acupuncture evidence cannot answer those questions.
Common pitfall: Natural origin does not establish safety, and a recommendation for one intervention cannot be generalized to another. The official ABA outline establishes the full examination scope, including complementary therapies; clinical recommendations require indication-specific evidence beyond the outline.
Pain Medicine Examination Content Outline — November 2024 · 2026 ACR Osteoarthritis Guideline Summary
Taxonomy: Classification of Pain Syndromes1%
31.Which mechanisms distinguish nociceptive, neuropathic, and nociplastic pain?
Nociceptive pain arises from actual or threatened damage to non-neural tissue with activation of nociceptors. Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. Nociplastic pain arises from altered nociception without clear evidence of tissue damage activating peripheral nociceptors or a somatosensory lesion or disease explaining the pain. These are mechanistic descriptors, and mechanisms may coexist. Match the label to positive clinical evidence rather than assigning neuropathic pain solely because symptoms sound unusual.
Apply it
A patient has painful knee osteoarthritis and a separate burning area with sensory loss after a documented nerve injury. Describe the distinct nociceptive and neuropathic contributors rather than forcing all symptoms into one mechanism.
Common pitfall: Normal imaging alone does not establish nociplastic pain. Burning language alone does not establish neuropathic pain without evidence linking symptoms to somatosensory disease or injury.
Chronic Widespread Pain Syndromes1%
32.What symptom cluster supports recognition of fibromyalgia?
Fibromyalgia commonly combines widespread pain with fatigue, unrefreshing sleep, and cognitive difficulties. Symptoms extend beyond one injured tissue or peripheral nerve territory, and their combined burden helps distinguish the syndrome from a purely local pain generator. NIAMS emphasizes a broad management approach that can include exercise, psychological treatment, medication, and self-management. Recognition does not mean every subsequent symptom belongs to fibromyalgia; focal neurological deficits, inflammatory findings, or other new features still require their own assessment.
Apply it
A patient describes pain across multiple body regions, poor sleep, fatigue, and difficulty concentrating. Assess the syndrome as a whole and its functional impact while checking whether any focal finding suggests an additional disorder requiring separate investigation.
Common pitfall: A widespread pain diagnosis should neither depend on finding one structural lesion nor become an explanation for every new complaint without examination and clinical reassessment.
Acute Pain, Pain due to Trauma, and Procedural Pain6.5%
33.How should buprenorphine be approached before surgery?
Multisociety recommendations advise against routinely discontinuing buprenorphine in the perioperative period, particularly when it treats opioid use disorder. Stopping it can jeopardize continuity of treatment and increase the risk of recurrence of opioid use. Plan analgesia in advance using multimodal and regional approaches when appropriate, with coordination among surgical, anesthesia, pain, and outpatient treatment teams. Continuing buprenorphine does not mean postoperative pain requires no assessment or that additional analgesic treatment can never be needed.
Apply it
A patient stable on buprenorphine for opioid use disorder is scheduled for surgery. Coordinate a perioperative plan that generally maintains treatment, anticipates pain needs, and identifies who will manage medication decisions during admission and after discharge.
Common pitfall: Routine discontinuation to make all opioid receptors available overlooks recurrence risk and treatment continuity. Continuing buprenorphine also does not substitute for an adequate postoperative analgesic plan.
ASRA Multisociety Recommendations on Perioperative Buprenorphine
34.Why should postoperative analgesia be assessed during activity?
Resting pain can underestimate the interference that matters during postoperative recovery. Assess pain with relevant activities, such as coughing, transferring, or mobilizing, alongside sedation and other adverse effects. The outline emphasizes both efficacy and safety monitoring and the role of analgesia in enhanced recovery. A clinically useful regimen supports recovery tasks without unacceptable toxicity. A low resting score with poor movement tolerance should prompt reassessment of the plan rather than being treated as complete analgesic success.
Apply it
A postoperative patient reports little pain while lying still but cannot cough or transfer because of pain. Reassess activity-related analgesia and safety, then adjust the coordinated plan around recovery tasks rather than relying solely on the resting score.
Common pitfall: Aiming for zero pain at rest can encourage excessive sedation. Functional recovery and safe participation provide essential information that a resting intensity score cannot supply.
Pain Medicine Examination Content Outline — November 2024 · ASRA Perioperative Management of Patients on Buprenorphine for Opioid Use Disorder
35.How is multimodal acute analgesia selected?
Multimodal analgesia combines appropriate treatments with different therapeutic roles to improve pain control and recovery while limiting reliance on a single agent. Selection depends on the operation, pain mechanism, organ function, respiratory risk, patient preferences, and available expertise. The outline includes regional techniques, nonopioid medicines, opioids, and nonpharmacological approaches. Each component needs its own indication and safety review; adding multiple sedating drugs without considering interactions is not automatically a safer or more effective multimodal strategy.
Apply it
A patient facing painful surgery has chronic lung disease and impaired kidney function. Build a procedure-specific plan using suitable regional and nonpharmacological options, and select medicines around both respiratory and renal risks rather than adding a standard drug bundle.
Common pitfall: More drug classes do not necessarily mean better multimodal care. Shared adverse effects and contraindications can outweigh theoretical benefits when a standard bundle ignores individual vulnerabilities.
Pain Medicine Examination Content Outline — November 2024 · ASRA Perioperative Management of Patients on Buprenorphine for Opioid Use Disorder · FDA Gabapentinoid Drug Safety Communication — Serious Breathing Problems
36.What makes postoperative discharge a treatment transition?
Postoperative discharge transfers responsibility for analgesia and any ongoing treatment for opioid use disorder. ASRA emphasizes communication with the outpatient buprenorphine prescriber, including the discharge opioid plan and continuation of maintenance treatment. Reconcile medicines, clarify intended short-term therapy, identify follow-up responsibility, and ensure the patient understands changes. A written list alone is insufficient when different teams hold conflicting assumptions. Clear handoffs reduce the chance that temporary postoperative prescribing disrupts established treatment or persists without review.
Apply it
A patient receiving buprenorphine will leave hospital with an additional short-term analgesic. Contact the outpatient prescriber, reconcile the discharge plan, and clarify follow-up and responsibility so the patient receives one understandable set of medication instructions.
Common pitfall: Assuming the outpatient team will infer inpatient changes invites gaps and duplication. Discharge communication should describe the actual plan rather than merely naming the medications.
ASRA Perioperative Management of Patients on Buprenorphine for Opioid Use Disorder
Musculoskeletal Pain12.5%
37.Which symptom pattern suggests lumbar spinal stenosis?
Lumbar spinal stenosis can produce leg pain, numbness, or weakness associated with standing or walking and relieved by sitting or bending forward. This posture-dependent pattern supports neurogenic claudication and should be correlated with examination and relevant imaging. Distance limitation alone is insufficient because vascular disease and other disorders can also limit walking. Assess whether posture changes symptoms, identify neurological findings, and look separately for progressive weakness or bladder and bowel changes that alter urgency.
Apply it
An older adult develops bilateral leg discomfort while standing in queues and walking upright but improves when sitting or leaning over a shopping cart. Use the posture relationship to guide assessment for lumbar stenosis and alternative causes.
Common pitfall: Walking-related pain alone does not distinguish neurogenic from vascular claudication. An imaging report of narrowing also needs correlation with the patient's symptoms and examination.
38.When do bladder or saddle symptoms make back pain urgent?
New bladder dysfunction, altered saddle or genital sensation, or bowel and sexual changes accompanying back or leg symptoms can indicate cauda equina compression. Bladder symptoms may include difficulty initiating urination, reduced sensation of flow, or loss of normal awareness rather than established incontinence alone. These warning features require immediate assessment through an emergency pathway. Do not wait for every feature, severe weakness, or complete retention before escalating a presentation that raises concern for this time-sensitive neurological emergency.
Apply it
A patient with recent bilateral sciatica now reports reduced awareness of urination and numbness when wiping. Arrange immediate emergency assessment even though the patient can still walk and has not developed overt urinary incontinence.
Common pitfall: Preserved walking and absence of incontinence do not exclude cauda equina syndrome. Waiting for complete retention can delay assessment after earlier warning symptoms have appeared.
Torbay and South Devon NHS Foundation Trust — Cauda Equina Syndrome
39.When are topical NSAIDs favored for knee osteoarthritis?
The 2026 ACR summary strongly recommends topical NSAIDs for knee osteoarthritis and conditionally favors topical over oral NSAIDs. These are different statements: treatment efficacy can have a strong recommendation while the preference between routes remains conditional. Consider the painful joint, systemic risk, patient preferences, access, and response. Topical treatment is particularly relevant when limiting systemic exposure is desirable, but it still requires an individualized review and should accompany a broader plan that addresses function and self-management.
Apply it
A patient with symptomatic knee osteoarthritis wants medication and has concerns about systemic adverse effects. Discuss a topical NSAID within an exercise-centered plan, explaining that the route preference is conditional and should reflect the individual's circumstances.
Common pitfall: Do not describe the topical-over-oral preference as strong. Also avoid extrapolating a knee-specific recommendation to every deep joint or musculoskeletal pain condition without supporting evidence.
2026 ACR Osteoarthritis Guideline Summary · ACR Osteoarthritis Clinical Practice Guidelines
40.How do anatomical site and weight status shape osteoarthritis rehabilitation?
The 2026 ACR summary strongly recommends exercise for knee and hip OA. Hand exercise is conditionally recommended. Weight loss is strongly recommended for patients with knee or hip OA who meet overweight or obesity criteria; this is not a universal weight-loss instruction for every person with OA. Individualize exercise around capacity, preferences, and access. Walking limitations can justify mobility aids, while functional restrictions can support physical or occupational therapy referral. Earlier ACR guidance describes multiple exercise modalities and potential benefits of supervision.
Apply it
A patient with knee OA and obesity cannot sustain a demanding walking program. Select an accessible lower-load exercise approach, arrange appropriate rehabilitation support, and offer supported weight management. For a patient with hand OA, discuss hand exercise with its conditional recommendation and task-specific goals.
Common pitfall: Recommendation strength differs by joint and intervention. Weight management should support treatment rather than become a prerequisite for acknowledging symptoms or offering care.
2026 ACR Osteoarthritis Guideline Summary · 2019 ACR/Arthritis Foundation Guideline for Hand, Hip, and Knee Osteoarthritis
41.What different questions do spinal imaging and electrodiagnostic studies answer?
Imaging can demonstrate a structural lesion and its relationship to a spinal nerve or root. Electrodiagnostic findings can support objective neurological dysfunction but do not independently identify every structural cause or pain generator. Correlate each test with the clinical distribution and examination. IASP distinguishes identifying an affected nerve from identifying the lesion causing its symptoms. A concordant structural abnormality can support a causal diagnosis; an abnormality at a discordant level does not explain the presentation merely because it appears on the scan.
Apply it
A patient has focal weakness and sensory changes that do not match the most prominent MRI abnormality. Reconsider localization and use further assessment, including appropriate electrodiagnostic evaluation, to address the discrepancy before selecting an intervention at the imaged level.
Common pitfall: A test abnormality is not automatically the symptomatic lesion. Conversely, the absence of prominent pain does not remove the need to investigate objective neurological dysfunction.
PART_I-C.pdf · Pain Medicine Examination Content Outline — November 2024
42.How do radicular pain, radiculopathy, and somatic referred pain differ?
Radicular pain arises through ectopic activation of afferent fibers in a spinal nerve or its roots, rather than stimulation of their peripheral terminals. It is often lancinating and perceived along a narrow limb or trunk band. Radiculopathy is objective sensory or motor dysfunction from impaired conduction in a spinal nerve or root; pain and dysfunction can occur separately. Somatic referred spinal pain begins with nociceptor activation in spinal tissues and is perceived elsewhere through convergent processing. It is commonly deep and aching rather than evidence that the nerve supplying the painful distant region is injured.
Apply it
Compare a patient with shooting leg pain but preserved neurological function with one who has concordant weakness and sensory loss. Document radicular pain and radiculopathy separately. Deep diffuse thigh aching from a spinal structure requires comparison with somatic referred pain rather than automatic assignment to a root lesion.
Common pitfall: Pain extending into a limb does not by itself establish radiculopathy. Distribution alone also cannot reliably separate referred pain from ectopic neural pain without examining quality, neurological findings, and explanatory pathology.
43.Which musculoskeletal clues suggest a hereditary connective tissue disorder?
Recurrent dislocations, joint hypermobility, tissue fragility, and a relevant family history can shift assessment beyond a single local injury toward a hereditary connective tissue disorder. The outline includes Ehlers-Danlos syndrome, joint hypermobility syndrome, Marfan syndrome, and osteogenesis imperfecta as distinct entities. Their overlap does not make them interchangeable. Characterize joint, skin, skeletal, and functional findings and pursue the appropriate diagnostic evaluation instead of assigning a specific syndrome from flexibility alone or assuming every painful joint has the same mechanism.
Apply it
A patient reports recurrent atraumatic shoulder dislocations, unusually fragile skin, and similar problems in relatives. Expand the history and examination beyond the current shoulder complaint before selecting a rehabilitation plan or attributing symptoms to ordinary overuse.
Common pitfall: Hypermobility alone does not establish a particular inherited syndrome. Similar pain complaints can arise from disorders with different systemic features and diagnostic requirements that merit separate assessment.
Cancer Pain and Cancer-related Pain6%
44.How does breakthrough cancer pain differ from uncontrolled background pain?
Breakthrough pain is a transient exacerbation occurring despite otherwise controlled persistent pain. It can be spontaneous or associated with an activity or trigger. Persistent pain throughout the day suggests a different problem from isolated episodes, while predictable worsening before the next scheduled dose can indicate inadequate duration of baseline treatment. Characterize timing, triggers, duration, baseline control, and functional impact before modifying therapy. The pattern determines whether attention belongs mainly to background treatment, episodic management, or a newly emerging cause.
Apply it
A patient with cancer is comfortable most of the day but has brief severe pain during transfers. Document the movement trigger and episode pattern while reviewing baseline control, rather than assuming that every severe episode requires indiscriminate escalation of continuous therapy.
Common pitfall: Calling all severe cancer pain breakthrough pain obscures persistent under-treatment or end-of-dose patterns. Reassess the underlying cause when the timing or character changes substantially.
45.When should painful bone metastases prompt consideration of radiation?
Pain from a bone metastasis can require both symptom control and treatment directed at the lesion. NCI identifies palliative radiation as an important option for painful bone metastases. Review the location, imaging, prior treatment, goals, and possible structural or neurological complications with oncology. Analgesic adjustment alone may overlook an effective local treatment. Suspected fracture or spinal compression also changes the immediate pathway, so a focal painful lesion should be assessed for more than its numerical pain intensity.
Apply it
A patient has a newly painful, imaging-confirmed pelvic bone metastasis despite an established analgesic regimen. Discuss palliative radiation with oncology while maintaining symptom treatment and checking for mechanical instability or another complication that changes management.
Common pitfall: Escalating systemic analgesics alone can miss a lesion-directed option. Radiation planning also does not replace urgent evaluation when fracture or neurological compression is suspected.
46.How can cancer treatment itself become a pain generator?
Cancer-related pain can arise from the tumor, its complications, or treatment. Chemotherapy-associated neuropathy, radiation-related injury, and persistent postsurgical pain require a causal assessment distinct from assuming tumor progression. Timing relative to treatment, symptom distribution, examination, and disease status help distinguish contributors. Several mechanisms can coexist in the same patient, so successful tumor treatment does not guarantee pain resolution. Identify the likely generator before selecting disease-directed therapy, neuropathic treatment, rehabilitation, or a combination tailored to the person's goals.
Apply it
A cancer survivor develops symmetric distal burning and sensory changes after neurotoxic chemotherapy while the tumor remains controlled. Evaluate a treatment-related neuropathic contributor and functional consequences rather than interpreting persistent pain as proof of recurrent malignancy.
Common pitfall: Neither remission nor active cancer identifies the pain mechanism by itself. New symptoms still require assessment because treatment injury, recurrence, and unrelated disease can coexist.
NCI Cancer Pain — Health Professional PDQ · Pain Medicine Examination Content Outline — November 2024
Visceral Pain4%
47.Why can visceral pain be diffuse or referred?
Visceral pain often has poor localization and may be perceived at a site separate from the affected organ. Convergence of visceral and somatic input helps explain referred pain, while the clinical pattern can include autonomic symptoms and a deep, diffuse quality. Location alone therefore does not reliably identify the source. Integrate associated symptoms, examination, timing, and disease evidence, and distinguish visceral from abdominal wall or other somatic causes before treating pain solely according to where the patient points.
Apply it
A patient with known intra-abdominal disease describes deep discomfort extending beyond a precise anatomical spot. Assess the organ-related symptoms and examination together instead of selecting a superficial local treatment solely from the apparent surface location.
Common pitfall: Diffuse pain does not mean nonorganic pain. Referred location also cannot, by itself, establish which organ is diseased or exclude a separate somatic pain generator.
NCI Cancer Pain — Health Professional PDQ · Pain Medicine Examination Content Outline — November 2024
48.Which associated symptoms broaden assessment of chronic pancreatitis pain?
Chronic pancreatitis can cause upper abdominal pain that may extend to the back, but assessment should also address pancreatic dysfunction. Exocrine pancreatic insufficiency can develop when the pancreas does not provide enough digestive enzymes and may produce greasy stools, diarrhea, and weight loss. These features indicate a need to evaluate digestion and nutrition rather than treating pain intensity alone. Pain trajectories can vary, so changing symptoms or systemic illness also require reassessment rather than automatic attribution to stable chronic pancreatitis.
Apply it
A patient with chronic pancreatitis reports persistent upper abdominal pain, greasy stools, and unintentional weight loss. Evaluate for exocrine pancreatic insufficiency and nutritional consequences alongside the pain assessment rather than only intensifying analgesic medication.
Common pitfall: Greasy stools and weight loss are not simply measures of pain severity. A pain-focused visit can miss pancreatic dysfunction that requires its own evaluation and treatment.
NIDDK Symptoms and Causes of Pancreatitis · NIDDK Symptoms and Causes for Exocrine Pancreatic Insufficiency
Headache and Orofacial Pain3%
49.Which attack pattern supports cluster headache?
ICHD-3 describes cluster headache as severe or very severe unilateral orbital, supraorbital, or temporal pain lasting 15–180 minutes untreated. Attacks occur from once every other day to eight times daily and include ipsilateral autonomic features or restlessness or agitation. At least five attacks are required, with the presentation not better explained by another diagnosis. The combined pattern of duration, strict laterality, autonomic signs, and behavior is more discriminating than unilateral pain or tearing considered alone.
Apply it
A patient reports repeated 50-minute attacks of severe right orbital pain with right-sided tearing and pacing. Use attack duration, frequency, autonomic laterality, and restlessness to assess cluster headache while checking for a secondary explanation.
Common pitfall: Tearing alone is insufficient for classification. An attack lasting only seconds or a continuous unremitting headache needs a different diagnostic comparison despite a similar location.
ICHD-3 — Cluster Headache · The-International-Classification-of-Headache-Disorders-3rd-Edition-2018
50.When does triptan use meet medication-overuse headache criteria?
Triptan-overuse headache requires headache on at least 15 days per month in a person with a pre-existing primary headache, together with regular triptan use on at least 10 days per month for more than three months. Count days of use rather than the number of tablets taken on those days. The pattern should prompt a broader management review, including acute treatment exposure and preventive needs, rather than interpreting every increase in headache frequency as an independent new primary syndrome.
Apply it
A patient with migraine has headache on 19 days monthly and uses a triptan on 12 days monthly for five months. Recognize the medication-overuse pattern and review the overall headache plan using a calendar of headache and treatment days.
Common pitfall: Counting tablets instead of treatment days can misclassify exposure. Frequent triptan use without the required headache frequency or duration does not establish the complete diagnosis.
Neuropathic Pain8%
51.When do regional findings satisfy clinical Budapest criteria for CRPS?
Clinical Budapest criteria require continuing pain disproportionate to the inciting event, at least one reported symptom in three of four categories, at least one examination sign in two or more categories, and no other diagnosis that better explains the findings. The four categories are sensory, vasomotor, sudomotor/edema, and motor/trophic. Sensory findings include allodynia or hyperalgesia; vasomotor findings include temperature or color asymmetry; sudomotor/edema findings include swelling or sweating changes; motor/trophic findings include reduced range of motion, motor dysfunction, or skin, hair, or nail changes. Count affected categories rather than accumulating several findings within one category.
Apply it
After a wrist injury, a patient has continuing disproportionate regional pain and reports touch sensitivity, color changes, and swelling: symptoms in three categories. Examination shows brush allodynia and edema: signs in two categories. These findings meet the symptom and sign thresholds; diagnose CRPS only if no alternative, such as infection, vascular disease, or persisting local injury, better explains them.
Common pitfall: Allodynia alone is insufficient. Reported historical swelling is a symptom unless observed on examination, and multiple sensory abnormalities still count as only one category.
Budapest Criteria - European Pain Federation · Budapest Checklist - European Pain Federation
52.How does a distal polyneuropathy pattern guide assessment?
A distal, broadly symmetric pattern of painful sensory symptoms in a person with diabetes can support assessment for painful diabetic polyneuropathy. Examine sensation, distribution, function, and alternative explanations rather than attributing every limb symptom to diabetes. Markedly focal, asymmetric, or otherwise discordant findings warrant reconsideration of the proposed localization. Once the clinical diagnosis is established, treatment decisions should address pain, adverse effects, sleep, mood, and participation while remaining separate from the evaluation and management of the underlying neuropathy.
Apply it
A person with diabetes describes bilateral burning feet but also new isolated hand weakness. Assess the distal sensory syndrome and the focal motor complaint separately rather than assuming that one label adequately explains both clinical patterns.
Common pitfall: Diabetes is a risk factor, not proof that every neurological complaint is diabetic neuropathy. Distribution and examination remain necessary to identify additional or alternative disorders.
AAN Oral and Topical Treatment of Painful Diabetic Polyneuropathy — Practice Guideline Update · Pain Medicine Examination Content Outline — November 2024
53.When does persistent zoster pain qualify as postherpetic neuralgia?
CDC defines postherpetic neuralgia as pain continuing more than 90 days after the onset of the shingles rash. It usually involves the region affected by the rash and can persist long after skin lesions resolve. Older age and more severe acute pain or rash increase risk. Establish the rash timeline and anatomical relationship rather than diagnosing solely from healed skin. Pain during the acute infection and pain meeting the later postherpetic definition occupy different points in the disease course.
Apply it
Four months after a unilateral thoracic shingles eruption, a patient has persistent pain and touch sensitivity in the same area despite healed skin. Use the timing and distribution to recognize postherpetic neuralgia and assess its functional impact.
Common pitfall: A resolved rash does not mean the pain must have resolved. Conversely, pain early in an active shingles episode has not yet crossed the postherpetic timing threshold.
54.How does central neuropathic pain differ from central sensitization?
Central neuropathic pain requires a lesion or disease of the central somatosensory nervous system that explains the pain. Central sensitization describes increased responsiveness of central nociceptive neurons and does not itself establish such a lesion. A person with a relevant stroke or spinal cord lesion may have central neuropathic pain, whereas amplified pain processing can occur without that disease pattern. Separate the anatomical cause from the processing mechanism, and correlate symptoms with the known lesion and sensory examination.
Apply it
A patient has persistent painful altered sensation in a region affected by a documented central somatosensory lesion. Assess lesion-symptom concordance rather than using central sensitization and central neuropathic pain as interchangeable explanations for the same complaint.
Common pitfall: The word central does not make these concepts equivalent. Widespread sensitivity alone does not establish central neuropathic pain without an explanatory central somatosensory lesion or disease.
IASP Terminology · Pain Medicine Examination Content Outline — November 2024
55.Why should sleep and mood be assessed in painful diabetic neuropathy?
Painful diabetic polyneuropathy can interfere with sleep, mood, and daily participation, while these problems also influence the person's overall treatment experience. The AAN guideline recommends assessing concurrent mood and sleep disorders. Their presence can shape treatment priorities and medication selection, but does not make the neurological pain less credible. Follow these outcomes separately from pain intensity so that a modest analgesic change is not mistaken for adequate recovery when sleep, depressive symptoms, or daily function remain severely impaired.
Apply it
A patient's foot pain improves slightly with treatment, but insomnia and depressive symptoms remain disabling. Assess and address those problems explicitly while reviewing the analgesic plan, rather than declaring success from the small change in pain intensity.
Common pitfall: Mood assessment is part of comprehensive neurological pain care, not evidence against neuropathy. A single pain score cannot show whether sleep or psychological burden has improved.
AAN Oral and Topical Treatment of Painful Diabetic Polyneuropathy — Practice Guideline Update
Special Cases8%
56.How should developmental ability shape pediatric pain assessment?
Use self-report when the child understands the task. With the Faces Pain Scale–Revised, the child selects a face representing pain intensity; the clinician or parent does not select the face by matching the child's appearance. The Royal Children's Hospital lists faces scales for ages 3–18 years, subject to developmental suitability. FLACC is a clinician-rated observational instrument, listed for ages 2 months to 7 years: face, legs, activity, cry, and consolability each contribute 0–2 points, producing a 0–10 total. Revised FLACC supports assessment of nonverbal children, including those with developmental disability or cognitive impairment.
Apply it
A five-year-old who cannot use numerical ratings may still understand a faces scale and provide self-report. For a nonverbal child with cognitive impairment, use revised FLACC and caregiver information about usual behavior. Record observations at rest and during movement, then reassess after treatment. For example, FLACC category scores of 1, 1, 2, 1, and 1 total 6/10.
Common pitfall: Behavioral scores can reflect anxiety or other distress as well as pain; interpret them with the clinical cause and context. Quiet behavior does not exclude pain. Caregiver observations help interpret behavior but should not automatically replace a capable child's self-report.
Pain Medicine Examination Content Outline — November 2024 · IASP Announces Revised Definition of Pain · Clinical Practice Guidelines : Acute pain management
57.Why does medication review matter especially in older adults?
Older adults differ substantially in physiological reserve, cognition, function, and comorbidity, so chronological age alone cannot determine an analgesic plan. Review renal function, respiratory disease, concurrent sedatives, over-the-counter drugs, and functional consequences. FDA identifies older adults as particularly vulnerable to gabapentinoid-associated breathing problems, while NSAID safety changes with kidney function and volume status. Compare benefit with sedation, falls-related functional concerns, and treatment burden through individualized reassessment rather than applying one standard regimen to an age group.
Apply it
An older adult taking an opioid and gabapentin develops daytime somnolence during a dehydrating illness and also uses over-the-counter naproxen. Reconcile every medicine and reassess respiratory, renal, and functional risks before continuing the existing regimen.
Common pitfall: A previously stable prescription list can become unsafe when illness or organ function changes. Over-the-counter medicines and sedatives from other prescribers must remain part of assessment.
FDA Gabapentinoid Drug Safety Communication — Serious Breathing Problems · NIDDK Keeping Kidneys Safe: Smart Choices about Medicines · Pain Medicine Examination Content Outline — November 2024
58.How can pain be assessed when verbal communication is limited?
Inability to communicate verbally does not exclude pain. First determine whether supported communication or a simplified self-report method is possible, then integrate behavior, movement, known painful conditions, caregiver observations, and response to treatment. Compare findings with the person's baseline because behavior can have several causes. IASP explicitly recognizes pain in people unable to communicate. The goal is a structured, repeated assessment that neither ignores pain nor assumes every sign of distress necessarily has a painful cause.
Apply it
A person with advanced cognitive impairment grimaces during transfers and resists care, according to a caregiver who knows the baseline. Evaluate likely painful causes and reassess movement and behavior after an appropriate intervention rather than requiring a verbal score.
Common pitfall: Normal vital signs and absent speech do not establish comfort. Conversely, agitation alone should not end the differential assessment of delirium, fear, or other causes.
IASP Announces Revised Definition of Pain · Pain Medicine Examination Content Outline — November 2024
59.When should acute sickle cell pain be treated and reassessed?
ASH guidance calls for pain medication within one hour of arrival for acute sickle cell pain, followed by reassessment every 30–60 minutes. Prompt treatment and repeated evaluation should occur alongside assessment for complications and consideration of the individual's established treatment needs. A reassuring appearance or lack of dramatic vital-sign changes should not be used to invalidate the reported pain. The CDC outpatient opioid guideline excludes sickle cell disease, so its general framework should not replace disease-specific acute pain guidance.
Apply it
A patient with sickle cell disease arrives with severe familiar pain and stable vital signs. Begin timely treatment while evaluating for complications, then reassess at the recommended interval rather than waiting for visible distress to justify analgesia.
Common pitfall: Do not delay treatment until the patient appears sufficiently ill. A single administered dose without timely reassessment also fails to address evolving pain or inadequate response.
ASH Clinical Practice Guidelines on Sickle Cell Disease — What You Should Know · CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
60.How do access barriers change the meaning of treatment adherence?
Missed appointments or incomplete rehabilitation may reflect transport, language, cost, housing, disability, or caregiving barriers rather than unwillingness to improve. The outline explicitly includes social determinants, healthcare disparities, communication, and coordinated care. Ask what prevented participation and adapt the plan around feasible access while maintaining clinically appropriate goals. Document specific barriers and responsibilities for follow-up. This approach makes the treatment decision more accurate because apparent nonresponse cannot be interpreted reliably when the patient could not obtain the intended intervention.
Apply it
A patient labeled unmotivated has missed therapy because transport is unavailable and instructions were not understandable. Clarify these barriers, arrange suitable communication support, and redesign follow-up so the patient has a realistic opportunity to participate.
Common pitfall: Calling an inaccessible plan nonadherence mistakes a system barrier for a personal trait. Equal written instructions do not ensure equal understanding or practical access to care.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official outline as the full scope; allocate about half of study time to General and half to Clinical States.
- Give greatest depth to pharmacotherapy, procedural treatment, and musculoskeletal pain while maintaining coverage of every smaller domain.
- Connect sensory findings and lesion evidence to mechanism rather than diagnosing from pain adjectives alone.
- Compare representative agents across all four pharmacotherapy subsections, including mechanisms, interactions, contraindications, organ-function concerns, and partial response versus treatment failure.
- Match procedural targets to anatomy and use procedure-specific bleeding-risk classification alongside infection and thrombotic risk.
- Practise urgent distinctions: cauda equina warning symptoms, LAST, respiratory toxicity, and changes suggesting cancer complications.
- Apply the Budapest symptom and examination-sign thresholds, then connect CRPS assessment with rehabilitation, psychological care, procedural selection, and care transitions.
- Separate guideline populations and recommendation strength, including WHO primary low back pain, CDC exclusions, and site-specific ACR osteoarthritis recommendations.
A practical preparation plan
1. Map the full outline
Build a checklist from all 14 blueprint domains. Mark unaddressed topics, including additional drug mechanisms, advanced pharmacokinetics, other intervention techniques, pregnancy, research methods, and legal issues, for further study.
2. Build mechanism-based comparisons
For each syndrome, connect history, sensory examination, anatomical distribution, and disease evidence. Contrast nociceptive, neuropathic, and nociplastic contributors and record the finding that would change the working diagnosis.
3. Work through treatment decisions
For each medication or procedure, state the mechanism or anatomical target, intended benefit, measurable functional goal, organ-function or bleeding concern, alternative, and reassessment plan. Compare opioids, antipyretic analgesics, antidepressants/anticonvulsants, and other analgesic pharmacotherapy with comparable attention.
4. Rehearse safety pivots
Use brief cases to identify when routine pain care must change: new bladder or saddle symptoms, suspected infection, uncertain antithrombotic exposure, LAST, excessive sedation, dehydration with NSAIDs, and new focal cancer pain.
5. Complete and review the drills
Answer the 20 questions independently, then explain why each alternative is less appropriate. Track errors by domain and reasoning type rather than interpreting the small-set score as an examination prediction.
6. Expand beyond text-only practice
Use appropriate anatomy and clinical image resources, and revisit topics outside this selective guide. The official outline remains the full content checklist.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABA Pain Medicine Exam
- Pain Medicine Examination Content Outline — November 2024
- ABA Pain Medicine Exam Blueprint
- IASP Terminology
- IASP Announces Revised Definition of Pain
- FDA Gabapentinoid Drug Safety Communication — Serious Breathing Problems
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
- NIDDK Keeping Kidneys Safe: Smart Choices about Medicines
- ASRA Checklist for Treatment of Local Anesthetic Systemic Toxicity
- ASRA Local Anesthetic Systemic Toxicity Checklist — 2020, version 1.1
- FDA Kenalog-10 Prescribing Information — 2024
- ASRA Consensus Guidelines on SCS Patient Selection and Trial Stimulation
- WHO Releases Guidelines on Chronic Low Back Pain
- WHO Guideline for Non-surgical Management of Chronic Primary Low Back Pain
- Torbay and South Devon NHS Foundation Trust — Cauda Equina Syndrome
- 2019 ACR/Arthritis Foundation Guideline for Hand, Hip, and Knee Osteoarthritis
- NIAMS Spinal Stenosis
- ASRA Multisociety Recommendations on Perioperative Buprenorphine
- NCI Cancer Pain — Health Professional PDQ
- NIDDK Symptoms and Causes of Pancreatitis
- ICHD-3 — Triptan-overuse Headache
- ICHD-3 — Cluster Headache
- CDC Clinical Features of Shingles
- AAN Oral and Topical Treatment of Painful Diabetic Polyneuropathy — Practice Guideline Update
- NIAMS Fibromyalgia
- ACR Osteoarthritis Clinical Practice Guidelines
- 2026 ACR Osteoarthritis Guideline Summary
- FDA Caldolor (Ibuprofen) Prescribing Information — 2026
- NIDDK Definition and Facts for Peptic Ulcers
- NIDDK Symptoms and Causes for Exocrine Pancreatic Insufficiency
- ASH Clinical Practice Guidelines on Sickle Cell Disease — What You Should Know
- ASRA Perioperative Management of Patients on Buprenorphine for Opioid Use Disorder
- PART_I-C.pdf
- Chapter 15: Interpreting results and drawing conclusions | Cochrane
- The-International-Classification-of-Headache-Disorders-3rd-Edition-2018
- Important Patient and Consumer Information About Regenerative Medicine Therapies | FDA
- Updates to the ASRA Guidelines for Interventional Pain Procedures
- Budapest Criteria - European Pain Federation
- Budapest Checklist - European Pain Federation
- 1055
- Clinical Practice Guidelines : Acute pain management
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.